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at least two imaging studies in the first year. Imaging was 
recommended biannually during the second year and annu-
ally thereafter. The panel recommended FU by means of 
CT scan with slice thickness ≤3 mm (at least three phases 
with excretory phase if suspicion of collecting system 
involvement) or mpMRI. Annual checkup for pulmonary 
metastasis by CT thorax was advised. Outside study proto-
cols, biopsy during follow-up should only be performed in 
case of suspicion of residual/persistent disease or radiologi-
cal recurrence.
Conclusions The consensus led to clear FU recommenda-
tions after FT of renal masses supported by a multidisci-
plinary expert panel. In spite of the low level of evidence, 
these recommendations can guide clinicians and create uni-
formity in the follow-up practice and for clinical research 
purposes.
Keywords Focal therapy · Follow-up · Renal masses · 
Consensus · Delphi method
Abbreviations
CA  Cryoablation
CEUS  Contrast-enhanced ultrasound
Abstract 
Purpose To establish consensus on follow-up (FU) after 
focal therapy (FT) in renal masses. To formulate recom-
mendations to aid in clinical practice and research.
Methods Key topics and questions for consensus were 
identified from a systematic literature research. A Web-
based questionnaire was distributed among participants 
selected based on their contribution to the literature and/
or known expertise. Three rounds according to the Delphi 
method were performed online. Final discussion was con-
ducted during the “8th International Symposium on Focal 
Therapy and Imaging in Prostate and Kidney Cancer” 
among an international multidisciplinary expert panel.
Results Sixty-two participants completed all three rounds 
of the online questionnaire. The panel recommended a 
minimum follow-up of 5 years, preferably extended to 
10 years. The first FU was recommended at 3 months, with 
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CKD  Chronic kidney disease
FT  Focal therapy
HIFU  High-intensity focused ultrasound
IRE  Irreversible electroporation
KT  Key topic
MWA  Microwave
mpMRI  Multiparametric magnetic resonance imaging
PN  Partial nephrectomy
RCC  Renal cell cancer
RFA  Radio-frequency ablation
RM  Renal mass
RN  Radical nephrectomy
Introduction
Treatment of RMs has shifted from RN to nephron-spar-
ing interventions. Conversely, increasing life expectancy 
has resulted in increased number of elderly patients with 
multiple severe comorbidities and concomitant RM. In 
poor surgical candidates or patients suffering from a 
genetic predisposition for developing multiple tumors, 
FT competes strongly with minimally invasive surgery 
[1, 2]. Interest in kidney FT has been fueled by promising 
reports on mid- to long-term oncological outcome com-
bined with preservation or marginal loss of renal function 
[3–10].
The literature is abundant on safety and efficacy reports 
on CA and RFA. However, follow-up protocols are ill-
defined, and the major urological associations guidelines 
(EAU/AUA) provide sparse guidance on the subject [2, 
11, 12]. Efforts on standardization of terminology and 
reporting criteria by the “International Working Group on 
Image-Guided Tumor Ablation” have resulted in recom-
mendations that, although non-consensually structured, 
are valid so far [13, 14]. However, practical guidance in 
terms of follow-up schedules or specific tests is not pro-
vided. With the aim of filling this gap in follow-up rec-
ommendations after FT of RMs and to provide straight-
forward protocols, a multidisciplinary international 
consensus was organized on the subject of follow-up after 
FT in RMs.
Materials and methods
A consensus project based on the four Delphi method 
stages [15] was organized prior to and during the “8th 
International Symposium on Focal Therapy and Imaging in 
Prostate and Kidney Cancer” on June 21, 2015, in Noord-
wijk, The Netherlands. The four stages included:
1. Systematic literature search
 In order to assess the relevant literature, a systematic 
search of the PubMed database was conducted (date: 
January 2005–February 2015). The search focused on 
“renal masses” (and synonyms), “focal therapy” (and 
synonyms), and “follow-up” (and synonyms). The full 
search query and inclusion criteria to identify manu-
scripts are listed below (Table 1).
2. Defining consensus topics, formulating questions and 
selecting experts
 From the systematic literature review, key topics were 
identified, questions formulated, and online question-
naire created.
 Participants were selected based on their contribution 
to the literature, academic involvement or recognized 
expertise in the field. The multidisciplinary panel of 
experts in FT included urologists, radiologists, pathol-
ogists, radiation oncologists, and biomedical engineers. 
Biomedical engineers were asked for their involvement 
in new ablation technologies and diagnostics in the 
future.
3. Online questionnaires
 Three consecutive rounds of online questionnaires 
(www.surveymonkey.com) were sent to the selected 
experts in the period from March 29, 2015, till June 16, 
2015. In the first and second rounds, the participants 
were encouraged to provide suggestions and feedback. 
Results of the previous round were incorporated in 
successive rounds (2nd and 3rd). Questions on which 
consensus was not reached were reformulated, new 
questions incorporated following suggestions of the 
participants and similar questions collated.
4. Consensus meeting
 A 6-h consensus meeting to discuss the results of the 
questionnaire was conducted during the 8th International 
Symposium on “Focal Therapy and Imaging in Prostate 
and Kidney Cancer” in Noordwijk, The Netherlands 
(www.Focaltherapy.org) from June 21, 2015, to June 23, 
2015. During this last phase of the process, the results of 
the Web-based questionnaires were presented and dis-
cussed.
Results
Systematic literature search and key topics
Overall, 300 potentially eligible articles were identified by 
the systematic literature search. After review of titles and 
abstracts, 68 full-text articles were assessed for eligibility. 
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Finally, 31 publications were selected after quality assess-
ment (Addendum 1 in ESM). Most of these were case–
control and cohort studies describing a single type of FT, 
comparing FT to PN outcomes or laparoscopic versus per-
cutaneous approach. When assessing the follow-up topic, a 
lack of proper description of protocols was observed. Fur-
thermore, overlap between the definitions of residual/per-
sistent and recurrent disease frequently made it difficult to 
assess the results of these different outcomes separately.
Based on the lack of clarity from the literature search, 
we formulated five key topics. An additional query related 
to risk-adapted stratification follow-up showed up per-
sistently during the online survey and was incorporated 
among the key topics (Table 2).
Participants
From 130 experts invited, 76 (58 %) accepted to par-
ticipate in the project. The group consisted of 57 (75 %) 
urologists, 11 (14.5 %) radiologists, 5 (6.5 %) patholo-
gists, 2 (2.6 %) engineers and 1 (1.4 %) radiation oncolo-
gist. The experience of the participants with FT of renal 
masses was: CA for 82 %, RFA for 67 %, HIFU for 13 %, 
MWA for 10 % and IRE for 17 % of the participants.
First, second and third round questionnaires were 
completed by 72 (95 %), 67 (88 %) and 63 (83 %) of the 
experts, respectively. A total of 62 (82 %) participants com-
pleted all three rounds of the online questionnaire. A panel 
of 12 experts, consisting of 9 urologists, 1 pathologist, 1 
Table 1  Complete search query, filters used for the systematic literature search and inclusion criteria of the articles previous to identification of 
the key topics
Search query
(“Kidney neoplasms”[Mesh] OR kidney neoplasm*[tiab] OR kidney cancer*[tiab] OR kidney tumo*[tiab] OR kidney neoplasm*[tiab] OR 
kidney malignan*[tiab] OR kidney carcinoma*[tiab] OR kidney adenoma*[tiab] OR nephroma*[tiab] OR renal mass*[tiab] OR renal 
tumor*[tiab] OR renal tumor*[tiab] OR renal neoplasm*[tiab] OR renal cancer*[tiab] OR renal malignan*[tiab] OR renal carcinoma*[tiab] 
OR renal adenoma*[tiab]) AND (“Ablation Techniques”[Mesh] OR “Cryosurgery”[Mesh] OR cryotherap*[tiab] OR ablat*[tiab] OR 
cryoablat*[tiab] OR cryosurger*[tiab] OR RFA [tiab] OR radiofrequency ablat*[tiab] OR radio frequency ablat*[tiab] OR focal therap*[tiab]) 
AND (“follow-up studies”[Mesh] OR “minimally invasive surgical procedures”[Mesh] OR follow-up[tiab] OR follow-up[tiab] OR follow-up 
[tiab] OR CT [tiab] OR “tomography, X-ray computed”[Mesh] OR “ultrasonography”[Mesh] OR “magnetic resonance imaging”[Mesh] OR 
“biopsy”[Mesh] OR computed tomography[tiab] OR imaging[tiab] OR ultraso*[tiab] OR MRI[tiab] OR magnetic resonance imaging[tiab] OR 
biops*[tiab] OR “neoplasm recurrence, local”[Mesh] OR neoplasm persist*[tiab]) NOT (“animals”[Mesh] NOT “humans”[Mesh]) NOT  
(“letter” [Publication Type] OR “comment”[pt] OR “editorial”[pt])
Filters






Table 2  Key topics identified in the literature search and pertinent questions for follow-up
Key topic Questions
1. Definitions What is the proper definition of persistent/residual disease?
What is the proper definition of recurrent disease?
2. Follow-up intervals What is the first time point for imaging during follow-up?
What is the ideal follow-up interval?
What is the ideal length of follow-up?
3. Imaging modality Which one is the imaging modality of choice?
Which alternative imaging modality in case of CKD?
What are the proper CT/MRI protocols to be used?
Is radiation exposure an issue during the follow-up?
4. Follow-up for metastasis Which imaging test is recommended in the follow-up for metastasis?
Which is the recommended follow-up schedule for metastasis?
5. Role of biopsy in follow-up What is the role of biopsy in case of suspicion of residual/persistence or recurrence?
6. Risk stratification-adapted follow-up Should follow-up be adapted to risk stratification?
Which risk factors should be used?
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radiologist and 1 engineer/physicist, attended the consen-
sus meeting in Noordwijk. Addendum 2 in ESM lists par-
ticipants and their affiliations.
Consensus
In the online questionnaires, 98 % of the participants set 
the cutoff for consensus at ≥80 % agreement for a spe-
cific question. A total of 51 questions were considered for 
consensus. Online agreement and near-agreement were 
reached for 19 and 6 of the questions, respectively. Online 
agreement was not reached in 13 questions, and 13 were 
exploratory with multiple possible responses. Percentage of 
agreement and at which round it was reached are displayed 
in Addendum 3 in ESM.
There was online agreement on the lack of clear recom-
mendation on follow-up after FT, on a unique protocol after 
CA and RFA and on the multidisciplinary character of the 
follow-up protocol. During the present meeting, the com-
position of the follow-up team was defined as including 
at least one urologist, one radiologist and one pathologist 
with experience in FT.
KT 1. Definition of residual/persistent and recurrent 
disease
Residual or persistent disease was strictly defined as the 
“presence of any radiological enhancement at the first 
radiologic follow-up”. After consensus was reached on 
the timing of the first radiological FU (KT 2), the term “at 
3 months” was added (Table 3).
Online questionnaires showed agreement on that “any 
new enhancement inside the ablated zone or in the mar-
gin of the ablated zone after a period of non-enhancement, 
preferably with positive biopsy” was considered as locally 
recurrent disease. Of the participants, 57 % considered a 
growing mass without enhancement as recurrence, and 1/3 
of the participants would indicate a biopsy in this circum-
stance. Conversely, half of the participants did not consider 
biopsy mandatory for diagnosis of recurrence (Fig. 1a). 
The panel reviewed the definitions, results and suggestions 
and constructed a definition of radiological recurrence, 
as follows: “a new (after a period of non-enhancement) 
enhancing or growing lesion, inside or in the margin of the 
ablated zone” (Table 3).
Results of the online questionnaire and the panel meeting 
emphasized the differentiation between locally recurrent or 
“de novo” ipsilateral tumor (outside the treated area).
KT 2. Follow‑up intervals
The majority of the participants (74 %) recognized that con-
trast enhancement might persist several months after FT. 
During the consensus meeting, it was confirmed that a cer-
tain degree of tiny peripheral enhancement might be noted 
up to 6–9 months after FT that disappears subsequently. The 
opinion of the participants was divided at 40 % on the first 
timing for determination of residual disease (3 or 6 months 
after FT). The panel reached consensus on recommending 
first imaging after FT 3 months post-treatment.
No agreement was reached for number of radiologi-
cal FUs in the first year. Majority (69 %) favored biannual 
imaging in the first year post-treatment although, when 
asked in consecutive round to choose between three and 
two imaging studies during the first year, 56 % of the par-
ticipants supported imaging at 3, 6 and 12 months against 
36.5 % at 6 and 12 months. Based on this apparent discord-
ance, the panel recommended “at least” two imaging stud-
ies in the first year.
Table 3  Summary of definitions and follow-up recommendations
1. Definitions
 Residual/persistent disease: “presence of any radiological enhance-
ment at 3 months radiological follow-up”
 Radiological recurrence: “a new (after a period of non-enhance-
ment) enhancing or growing lesion, inside or in the margin of the 
ablated zone”
2. Multidisciplinary composition of follow‑up team




  Minimum FU period of 5 years, preferably extended to 10 years
  First FU imaging at 3 months post-treatment
  A minimum of two imaging studies in the first year
  Biannual imaging in the second year
  Annual imaging from the third year onwards
  Strongly advised not to skip on the minimum recommended num-
ber of imaging studies
 Imaging modalities
  First option 3-phase CT scan (non-enhanced, arterial and nephro-
graphic/cortico-medular), slice thickness ≤3 mm, IVP phase 
(delayed phase) advised if suspicion of urinary tract involvement 
or hydronephrosis
  Second option MRI with multiparametric protocol including at 
least: T1, T2, DWI, DCE
  In case of CKD 4/5 non-contrast-enhanced MRI or CEUS
 Follow-up of metastasis
  Annual examination for pulmonary metastasis, using CT thorax
  Besides chest and abdomen, no other routine imaging for distant 
metastasis
4. Biopsy
  Only in case of suspicion of residual disease/persistence or recur-
rence
5. Risk‑adapted follow‑up
 Stage and grade are main determinants
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Concerning imaging FU during the second year after 
FT, opinions were divided between biannually and annu-
ally (55 vs 43 %, respectively). After discussion on the 
risk of local radiological recurrence, the panel recom-
mended biannual imaging in the second year. From 
3 years onward, annual imaging was recommended by 
participants’ agreement (92.5 %) and supported by the 
panel.
The panel stressed the lack of reliable data in the liter-
ature, the need for more frequent imaging and prolonged 
FU in case of aggressive pathology (high grade and cT1b) 
(Fig. 1b), the lack of pathological staging in FT, and that 
eGFR should not dictate FU intervals.
Regarding the length of the follow-up after FT, the 
majority of participants favored 10 years (66 %). The panel 
recommended a minimum follow-up term of 5 years, with 
the advice to prolong to 10 years because of the absence of 
long-term data.
KT 3. Imaging modality
Considering participants’ response, the panel recom-
mended three-phase CT scan (non-enhanced, arterial, 
and nephrographic/cortico-medular) with ≤3 mm slice 
thickness protocol as the imaging of choice for the fol-
low-up after FT. Delayed or IVP phase was advised if 
suspicion of urinary tract involvement (leak or hydro-
nephrosis). The second preferred imaging modality was 
mpMRI (T1, T2, DWI and DCE sequences, 94 % con-
sensus) (Fig. 1d).
In case of CKD IV–V, the panel advised non-
contrast-enhanced MRI as the first choice instead of 
non-contrast-enhanced CT. Contrast-enhanced ultra-
sound (CEUS) was also considered as suitable option 
when available and if applied by experienced hands 
(Fig. 1c). Of participants, 80 % considered chang-
ing imaging policy on the basis of radiation expo-
sure. The panel emphasized that concerns on radia-
tion exposure must not lead to skip the minimum 
recommended amount of imaging studies, but rather 
to consider a different imaging modality (e.g., MRI 
for young age at FT or conditions at risk of radiation 
accumulation).
Follow-up intervals and type of imaging did not differ 
between CA and RFA.
KT 4. Follow‑up for metastasis
The majority of participants (77 %) recommended regular 
checkup for pulmonary metastasis, at yearly intervals (89 % 
agreement). Based on “near-consensus” online (79 %), the 
panel recommended the use of CT thorax instead of X-ray 
thorax because of its higher sensitivity. Besides imaging of 
chest and abdomen, no other routine follow-up for metasta-
sis is advised (consensus 83 %).
KT 5. The role of biopsy during follow‑up
Online agreement (85 %) was reached that post-FT biopsy 
should not be acquired routinely during follow-up. The 
participants agree (85 %) that the literature was not clear 
on the reliability of the biopsy to confirm residual disease. 
Biopsy was used by 72 % of participants to make the diag-
nosis or residual/recurrent disease and 2/3 recommended 
it for this indication. After discussion on the literature, the 
panel recommended biopsy during follow-up only if sus-
picion of residual/recurrent disease. Regarding the need to 
confirm radiological recurrence by biopsy, 51 % of online 
participants and the panel agreed that biopsies are not man-
datory to confirm recurrent disease. However, the panel 
strongly emphasized that biopsy might be of benefit to indi-
vidual patient counseling and treatment strategy.
Regarding initial biopsy results, the panel recommended 
to stop follow-up only in case of angiomyolipoma (Fig. 1e). 
In follow-up setting, opinions were divided on labeling 
biopsy as “non-diagnostic” in case of fibrosis, necrosis or 
inflammation on pathology. The panel could not find evi-
dence in the literature to solve this question.
KT 6. Risk stratification‑adapted follow‑up
There was online consensus (88 %) on “risk stratifica-
tion” to guide follow-up after FT in renal masses instead 
of depending on procedural quality control. There was an 
agreement that patient and tumor factors dictate additional 
testing. When ranking four possible stratification factors, 
1/3 of the participants found both stage and grade the most 
important, followed by RCC subtype. Clinical history of 
RCC was the least important. The panel agreed that patient 
and tumor factors should guide follow-up after FT, but con-
cern was expressed on the value of adapting the currently 
known risk factors to the more restrictive RM population 
treated by FT.
Discussion
Based on the Delphi methodology, an International mul-
tidisciplinary panel of experts discussed and formulated 
consensus definitions of residual/persistent and locally 
recurrent disease after FT of RMs. Recommendations were 
formulated for relevant key topics on FT follow-up includ-
ing the choice of imaging modality, follow-up intervals, 
checkup for metastasis and the role of biopsy. Furthermore 
the consensus unveiled that after FT, stage and grade are 
the main drivers of additional testing during follow-up. The 
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Fig. 1  Composite figure of questions from the Delphi survey
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presented recommendations avoid overlap between residual 
and recurrent disease definitions and represent a compre-
hensive quality of care document.
So far, no formal recommendation process has been 
undertaken for follow-up of RMs after FT although the 
International Working Group on Image-Guided Tumor 
Ablation previously presented a consensus document for 
standardization in terminology and reporting criteria for FT 
in general [13, 14, 16]. EAU and AUA guidelines on RCC 
advise risk-adapted follow-up considering ablated tumors 
as intermediate- and low-risk category [2, 11, 12]. The aim 
of the present consensus was neither to interfere with pre-
vious documents nor to define imaging patterns of persis-
tence or recurrence or specific recommendations on how 
to interpret a given test. For this purpose, a whole body of 
descriptive literature on post-FT imaging patterns for CT 
scan and MRI exists [17]. Conversely, the consensus aimed 
to establish clear and concise definitions of persistent and 
recurrent disease and to produce recommendations on 
which and when to apply alternative tests during FU.
Because of the absence of a well-designed compara-
tive diagnostic study in follow-up after kidney FT and the 
difficulty in applying a reliable standard for comparison, 
we choose the Delphi method as an adequate tool to draw 
recommendations based on expert opinion in the medical 
field [15, 18]. By reformulating the questions, providing 
the answers of the previous rounds and narrowing the pos-
sibility for feedback, the process of achieving consensus 
was stimulated. Two facts strengthened the present con-
sensus recommendations, the interdisciplinary character 
of the consensus Panel meeting and the high response rate 
reached during the three online rounds. Rather unusual 
in medical questionnaires, this high response rate likely 
reflects the strong interest and commitment of the partici-
pants [19, 20]. Furthermore, the participant’s comments 
forced the inclusion and discussion of a new topic: the risk-
adapted follow-up. Although agreement is not necessary 
to reach a consensus, participants massively set a cutoff at 
≥80 % as an agreement facilitating the discussion and the 
recommendation process.
After FT, tumor activity relies mostly on radiological 
evolution of the treated lesion after contrast administra-
tion. The need for repeated imaging during FT follow-up 
was early recognized and fully accepted. The panel agreed 
unanimously that a clear distinction between persistent/
residual disease and local recurrence was necessary. These 
definitions coincide with the ones previously stated by 
other panels composed mainly by radiologists [13].
Follow-up schedules after FT have been erratically 
described and not standardized. It distillates from the lit-
erature that early contrast evaluation within the first month 
after treatment may not be representative of the second-
ary vascular necrosis and apoptotic phenomenon that 
ultimately condition the evolution of the ablated lesion [21, 
22]. Three months was unanimously chosen as the moment 
for the first evaluation outside trial protocols irrespective of 
the ablation technology used, recognizing that the size of 
the lesion may be larger at this point. Rather than estab-
lishing a rigid imaging interval, the panel emitted minimal 
recommendations for both the period (minimum of 5 years) 
and interval (minimum of 2 imaging studies in the first 
year). Recent data suggesting that 5-year follow-up may 
miss up to 30 % of the recurrences in T1 tumors [23] sup-
port this recommendation especially in young or healthy 
patients treated by FT.
A significant percentage of patients with ablated renal 
masses are already known with CDK ≥ 3 at the moment 
of diagnosis, or will develop CKD ≥ 3 during the follow-
up. The toxicity of iodine contrast agents adds to the radia-
tion burden especially when long survival is expected [24]. 
Both concerns are solved by using mpMRI with or without 
contrast, although availability and costs may constrain the 
use. CEUS is the alternative test recommended by the con-
sensus. However, this test is not available in all countries 
worldwide for renal tumor diagnostics or follow-up and 
expert interpretation is needed [25].
Data gathered by the consensus also clarifies the role of 
the biopsy during follow-up. Not mandatory to pronounce 
the diagnosis of “radiological recurrence”, the panel con-
sidered that the majority of participants used biopsy as a 
tool to definitive diagnosis of residual/recurrent disease and 
when growing mass without evidence of enhancement. In 
view of the scarce publications on the subject, the panel 
recognized that there may be a poor correlation between 
radiographic imaging and histopathology of the biopsy 
post-RFA, but probably not for Cryoablation [3, 26]. The 
panel recommended unanimously biopsy during FU in case 
of radiological suspicion of recurrence. With the limita-
tions of expert opinion level of evidence, this seems to be 
the general policy in those centers practicing FT. Lastly, 
participants and the panel recommended stopping follow-
up only in those cases with initial biopsy showing angio-
myolipoma. The panel, considering the online results, rec-
ommended follow-up in case of any other biopsy results 
at treatment. However, in view that 56 % of respondents 
would stop follow-up when initial diagnostic of oncocy-
toma, the panel acknowledged that future studies should 
address this specific point. In spite of some data reporting 
the high reliability of oncocytoma diagnosis, the current 
pathology guidelines advise the use of the term “onco-
cytic features” specifying the preference for oncocytoma or 
chromophobe RCC [27].
The key topic of “risk stratification” as a guide for fol-
low-up schedules after FT in RMs was strongly supported 
(88 %) in the first round of the consensus. The concept was 
extended in successive rounds according to participants’ 
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feedback. It was the unanimous opinion that both patient 
and tumor factors should guide the risk stratification. Spe-
cifically, tumor characteristics overpowered the reliability 
of the procedural ablation, and tumor stage and grade were 
the main drivers of a “risk stratification” adapted follow-up. 
These two factors are universally recognized in the follow-
up of any RCC, and size and stage are the most important 
risk factors for recurrence after kidney FT [4, 5, 28, 29]. 
In FT, information on grade is depending exclusively on 
biopsy with the consequent limitations in terms of accuracy 
and diagnostic yield [30]. The panel emphasized the impor-
tance of the subject and the need to strive to define “risk 
profiles” in the FT subpopulation of clinical renal tumors, 
mainly cT1a in which the classical “risk stratification” fac-
tors may require refinements.
Limitations
In spite of its strength, the Delphi methodology is not 
exempt of limitations. A consensus has low level of evi-
dence but reflects clinical practice in a topic where no RCT 
or well-conducted studies exist. In our specific topic, there 
is no literature comparing the efficacy of different follow-
up schedules after FT. One should question whether such 
a study makes sense and will ever show a sound clinical 
or statistical result for an event (persistence or local recur-
rence) that presents scarcely in the follow-up [31].
Arguments may arise on the composition of the panel. 
Major difference from our expert panel when compared 
with previous ones on kidney FT is the high prevalence of 
urologists. Although there seems to be a trend from lapa-
roscopic to percutaneous FT, it is still the responsibility 
and privilege of the urologist to follow up patients with 
localized kidney cancers after curative treatment. Thus, the 
panel composition and the strong recommendation on mul-
timodal composition of the team performing the follow-up 
rather represent a strong than a weak point.
Lastly, the key topic “risk stratification” was explored 
based on participants’ feedback. While recognizing the 
importance of patient factors as follow-up tailoring to 
our surprise, previous history of RCC was ranked as the 
least important by almost 2/3 of the participants. Age and 
comorbidity were not truly explored due to complexity of 
the subject and the length of the survey. The panel recog-
nized the importance of patients’ factors as determinants of 
a less stringent follow-up in clinical practice, but stressed 
the lack of a proper classification of such factors.
Conclusions
The present consensus document defines the concepts of 
residual (persistent) and recurrent disease after FT of a 
renal mass. It recommends minimum time intervals and 
type of imaging to be performed during the first 5 years of 
follow-up. Biopsy is recommended to confirm radiological 
recurrence, and an extended follow-up to 10 years is advis-
able due to the lack of long-term data. Imaging options in 
case of CKD ≥3 or because of radiation exposure concerns 
were discussed. “risk stratification” according to patient 
and tumor characteristics was strongly supported by par-
ticipants and the panel with so far only tumor factors (stage 
and grade) defined as stratifying forces.
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